NCT06262139View on ClinicalTrials.gov

Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 25, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
MRI Scan
Interventions
DRUG

MT218 injection

a targeted magnetic resonance imaging contrast agent

Trial Locations (1)

30322

RECRUITING

Emory University, Atlanta

All Listed Sponsors
collaborator

Emory University

OTHER

lead

Songqi Gao

INDUSTRY